DK3103443T3 - Fremgangsmåde til behandling af primær søvnforstyrrelse - Google Patents

Fremgangsmåde til behandling af primær søvnforstyrrelse Download PDF

Info

Publication number: DK3103443T3
Authority: DK; Denmark
Prior art keywords: procedure; sleep disorder; treating primary; primary sleep; treating
Prior art date: 2001-08-14

Application number

DK16172415.8T

Other languages

English (en)

Inventor

Nava Zisapel

Original Assignee

Neurim Pharmaceuticals 1991 Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-08-14

Filing date

2002-08-12

Publication date

2021-08-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11075696&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3103443(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-08-12 Application filed by Neurim Pharmaceuticals 1991 Ltd filed Critical Neurim Pharmaceuticals 1991 Ltd

2021-08-30 Application granted granted Critical

2021-08-30 Publication of DK3103443T3 publication Critical patent/DK3103443T3/da

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Pain & Pain Management (AREA)
Inorganic Chemistry (AREA)
Psychiatry (AREA)
Anesthesiology (AREA)
Heart & Thoracic Surgery (AREA)
Obesity (AREA)
Diabetes (AREA)
Rheumatology (AREA)
Hematology (AREA)
Cardiology (AREA)
Child & Adolescent Psychology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Separation Using Semi-Permeable Membranes (AREA)

DK16172415.8T 2001-08-14 2002-08-12 Fremgangsmåde til behandling af primær søvnforstyrrelse DK3103443T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IL144900A IL144900A (en)	2001-08-14	2001-08-14	Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs
EP02760523.7A EP1441702B1 (en)	2001-08-14	2002-08-12	Method for treating primary insomnia

Publications (1)

Publication Number	Publication Date
DK3103443T3 true DK3103443T3 (da)	2021-08-30

Family

ID=11075696

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK02760523.7T DK1441702T3 (da)	2001-08-14	2002-08-12	Fremgangsmåde til behandling af primær søvnløshed
DK16172415.8T DK3103443T3 (da)	2001-08-14	2002-08-12	Fremgangsmåde til behandling af primær søvnforstyrrelse

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
DK02760523.7T DK1441702T3 (da)	2001-08-14	2002-08-12	Fremgangsmåde til behandling af primær søvnløshed

Country Status (35)

Country	Link
US (1)	US8962024B2 (da)
EP (2)	EP1441702B1 (da)
JP (1)	JP2005501095A (da)
KR (1)	KR20040032917A (da)
CN (1)	CN100453078C (da)
AR (1)	AR034975A1 (da)
AU (1)	AU2002326114C1 (da)
BR (1)	BR0211855A (da)
CA (1)	CA2454699C (da)
CL (1)	CL2002001701A1 (da)
CR (1)	CR7271A (da)
CY (2)	CY1118924T1 (da)
DK (2)	DK1441702T3 (da)
EA (1)	EA200400302A1 (da)
ES (2)	ES2626591T3 (da)
GT (1)	GT200200164A (da)
HU (1)	HU230786B1 (da)
IL (1)	IL144900A (da)
IS (1)	IS3004B (da)
JO (1)	JO3446B1 (da)
LT (1)	LT1441702T (da)
MX (1)	MXPA04001372A (da)
NO (1)	NO334788B1 (da)
NZ (1)	NZ531318A (da)
PA (1)	PA8552301A1 (da)
PE (1)	PE20030331A1 (da)
PL (1)	PL367872A1 (da)
PT (2)	PT3103443T (da)
PY (1)	PY0218122A (da)
RU (1)	RU2560840C2 (da)
SI (1)	SI1441702T1 (da)
UA (1)	UA87262C2 (da)
UY (1)	UY27401A1 (da)
WO (1)	WO2003015690A2 (da)
ZA (1)	ZA200402005B (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL144900A (en)	2001-08-14	2013-12-31	Neurim Pharma 1991	Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs
IL149377A (en) *	2002-04-28	2012-10-31	Neurim Pharma 1991	Pharmaceutical formulation comprising melatonin for the potentiation of the effect of hypnotic compounds
AR056076A1 (es) *	2005-09-20	2007-09-19	Takeda Pharmaceutical	Agente profilactico o terapeutico para el desorden de sueno
US20070088079A1 (en) *	2005-09-20	2007-04-19	Takeda Pharmaceutical Company Limited	Prophylactic or therapeutic agent for sleep disorder
US7678808B2 (en)	2006-05-09	2010-03-16	Braincells, Inc.	5 HT receptor mediated neurogenesis
WO2008116004A2 (en)	2007-03-19	2008-09-25	Vita Sciences, Llc	Transdermal patch and method for delivery of vitamin b12
US20080248106A1 (en)	2007-04-05	2008-10-09	Marvin Heuer	Melatonin-based composition for improved sleep
WO2008122102A1 (en) *	2007-04-05	2008-10-16	Iomedix Development International Srl	Melatonin-based composition for improved sleep
US9532952B2 (en)	2011-01-28	2017-01-03	Physician's Seal, LLC	Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients
US8691275B2 (en) *	2011-01-28	2014-04-08	Zx Pharma, Llc	Controlled-release melatonin compositions and related methods
US10849856B2 (en)	2016-10-31	2020-12-01	Neurim Pharmaceuticals Ltd.	Melatonin mini-tablets and method of manufacturing the same
DK3337462T3 (da)	2016-10-31	2020-10-12	Neurim Pharma 1991	Melatonin-minitabletter og fremgangsmåde til fremstilling heraf

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3126375A (en)		1964-03-24		Chioacyl
US2789118A (en)	1956-03-30	1957-04-16	American Cyanamid Co	16-alpha oxy-belta1, 4-pregnadienes
US2990401A (en)	1958-06-18	1961-06-27	American Cyanamid Co	11-substituted 16alpha, 17alpha-substituted methylenedioxy steroids
US3048581A (en)	1960-04-25	1962-08-07	Olin Mathieson	Acetals and ketals of 16, 17-dihydroxy steroids
US3749712A (en)	1970-09-25	1973-07-31	Sigma Tau Ind Farmaceuti	Triamcinolone acetonide esters and process for their preparation
SE378109B (da)	1972-05-19	1975-08-18	Bofors Ab
US3996359A (en)	1972-05-19	1976-12-07	Ab Bofors	Novel stereoisomeric component A of stereoisomeric mixtures of 2'-unsymmetrical 16,17-methylenedioxy steroid 21-acylates, compositions thereof, and method of treating therewith
SE378110B (da)	1972-05-19	1975-08-18	Bofors Ab
JPS6045513A (ja) *	1983-05-18	1985-03-12	モナシユ　ユニバ−シテイ	身体行動および機能の日周期の不調を軽減する薬剤
US4600723A (en) *	1983-05-18	1986-07-15	Monash University	Method for minimizing disturbances in circadian rhythms of bodily performance and function
EP0126630B1 (en)	1983-05-18	1987-09-16	Monash University	The use of melatonin for the manufacture of a medicament
US5151446A (en)	1989-09-25	1992-09-29	Northwestern University	Substituted 2-amidotetralins as melatonin agonists and antagonists
FR2658818B1 (fr)	1990-02-27	1993-12-31	Adir Cie	Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5707652A (en)	1990-12-04	1998-01-13	State Of Oregon	Methods of treating circadian rhythm phase disorders
US5591768A (en) *	1990-12-04	1997-01-07	State Of Oregan, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University	Methods for treating circadian rhythm phase disturbances
DE69229490T2 (de)	1991-05-09	2000-02-17	Neurim Pharmaceuticals (1991) Ltd., Tel Aviv	Melatonin enthaltende Arzneimittel
IT1251544B (it) *	1991-05-13	1995-05-17	Gabriele Biella	Composizioni farmaceutiche attive nella terapia dei disturbi del sonno comprendenti melatonina o un suo derivato in associazione con un derivato benzodiazepinico
FR2680507B1 (fr)	1991-08-23	1993-10-08	Adir Cie	Nouvelles naphtylethylurees et naphtylethylthiourees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
DK0565296T3 (da) *	1992-04-07	1996-12-09	Neurim Pharma 1991	Anvendelse af melatonin til fremstilling af et lægemiddel til behandling af godartet prostatahyperplasi
US5449683A (en)	1992-10-01	1995-09-12	Massachussetts Institute Of Technology	Methods of inducing sleep using melatonin
IL103411A (en)	1992-10-11	1996-11-14	Neurim Pharma 1991	Melatonin Controlled Pharmacy Preparation for the Correction of Melatonin Deficiency or Distortion in Melatonin in Human Plasma
TW370529B (en)	1992-12-17	1999-09-21	Pfizer	Pyrazolopyrimidines
DK0674624T3 (da)	1992-12-17	1999-09-13	Pfizer	Pyrazoler med CRF-antagonistisk aktivitet
TW336932B (en)	1992-12-17	1998-07-21	Pfizer	Amino-substituted pyrazoles
BR9307646A (pt)	1992-12-17	1999-05-25	Pfizer	Pirrolopirimidinas como antagonistas de crf
KR100190730B1 (ko)	1992-12-17	1999-06-01	디. 제이. 우드, 스피겔 알렌 제이	부신피질 호르몬 유리인자(crf) 길항물질로서 치환된 피라졸
WO1995003043A1 (en)	1993-07-26	1995-02-02	State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University	Sustained release oral compositions containing melatonin
US5654325A (en)	1993-11-18	1997-08-05	Eli Lilly And Company	Melatonin derivatives for use in treating sleep disorders
US5403851A (en)	1994-04-05	1995-04-04	Interneuron Pharmaceuticals, Inc.	Substituted tryptamines, phenalkylamines and related compounds
US6469044B1 (en)	1995-02-01	2002-10-22	Neurim Pharmaceuticals (1991) Ltd.	Method for treating patients suffering from drug dependencies which lead to plasma melationin deficiencies
US5688520A (en) *	1995-03-29	1997-11-18	Minnesota Mining And Manufacturing Company	Transmucosal delivery of melatonin for prevention of migraine
EP0748627A3 (en)	1995-06-14	1997-05-21	Lilly Co Eli	Melatonin agonists for the treatment of benign forms of hyperplasia of the prostate
NO981489L (no) *	1995-10-03	1998-05-22	Interneuron Pharma	Blandinger av melatonin og analgetika samt anvendelser derav
EP0912174B1 (en) *	1996-07-17	2004-04-28	MERCK & CO., INC.	Alteration of circadian rhythmicity with non-peptidal neurikinin-1 receptor antagonists
US5776969A (en)	1997-02-27	1998-07-07	Eli Lilly And Company	Treatment of sleep disorders
US5826408A (en) *	1997-05-08	1998-10-27	Riverwood International Corporation	Rotary flap tucker for a cartoning machine
US6472421B1 (en)	1998-11-13	2002-10-29	Nymox Corporation	Methods for treating, preventing, and reducing the risk of the onset of alzheimer's disease using an HMG CoA reductase inhibitor
IL150190A0 (en) *	2000-01-05	2002-12-01	Neurim Pharma 1991	Method and formulation for treating resistance to antihypertensives and related conditions
IL144900A (en)	2001-08-14	2013-12-31	Neurim Pharma 1991	Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs
US6703412B1 (en)	2002-09-27	2004-03-09	Holly A. Rosenthal	Method of treating sleeplessness with melatonin on an acute basis
CA2850162A1 (en)	2011-09-27	2013-04-04	IBIS Medical, Inc.	Intragastric implant devices

2001
- 2001-08-14 IL IL144900A patent/IL144900A/en active IP Right Grant
2002
- 2002-07-29 UY UY27401A patent/UY27401A1/es not_active Application Discontinuation
- 2002-07-29 PY PY200200218122A patent/PY0218122A/es unknown
- 2002-07-31 CL CL2002001701A patent/CL2002001701A1/es unknown
- 2002-08-05 AR ARP020102964A patent/AR034975A1/es not_active Application Discontinuation
- 2002-08-08 JO JOP/2002/0086A patent/JO3446B1/ar active
- 2002-08-09 PA PA20028552301A patent/PA8552301A1/es unknown
- 2002-08-12 PT PT161724158T patent/PT3103443T/pt unknown
- 2002-08-12 DK DK02760523.7T patent/DK1441702T3/da active
- 2002-08-12 RU RU2011131532/15A patent/RU2560840C2/ru active
- 2002-08-12 NZ NZ531318A patent/NZ531318A/en not_active IP Right Cessation
- 2002-08-12 CA CA2454699A patent/CA2454699C/en not_active Expired - Lifetime
- 2002-08-12 EP EP02760523.7A patent/EP1441702B1/en not_active Revoked
- 2002-08-12 ES ES02760523.7T patent/ES2626591T3/es not_active Expired - Lifetime
- 2002-08-12 SI SI200231087T patent/SI1441702T1/sl unknown
- 2002-08-12 MX MXPA04001372A patent/MXPA04001372A/es unknown
- 2002-08-12 HU HU0401042A patent/HU230786B1/hu unknown
- 2002-08-12 EP EP16172415.8A patent/EP3103443B1/en not_active Revoked
- 2002-08-12 CN CNB028158326A patent/CN100453078C/zh not_active Ceased
- 2002-08-12 DK DK16172415.8T patent/DK3103443T3/da active
- 2002-08-12 EA EA200400302A patent/EA200400302A1/ru unknown
- 2002-08-12 BR BR0211855-6A patent/BR0211855A/pt not_active Application Discontinuation
- 2002-08-12 PL PL02367872A patent/PL367872A1/xx not_active Application Discontinuation
- 2002-08-12 KR KR10-2004-7002245A patent/KR20040032917A/ko not_active Ceased
- 2002-08-12 WO PCT/IL2002/000662 patent/WO2003015690A2/en not_active Ceased
- 2002-08-12 ES ES16172415T patent/ES2882584T3/es not_active Expired - Lifetime
- 2002-08-12 IS IS7136A patent/IS3004B/is unknown
- 2002-08-12 AU AU2002326114A patent/AU2002326114C1/en not_active Expired
- 2002-08-12 LT LTEP02760523.7T patent/LT1441702T/lt unknown
- 2002-08-12 PT PT2760523T patent/PT1441702T/pt unknown
- 2002-08-12 US US10/486,688 patent/US8962024B2/en active Active
- 2002-08-12 JP JP2003520451A patent/JP2005501095A/ja active Pending
- 2002-08-13 GT GT200200164A patent/GT200200164A/es unknown
- 2002-08-13 PE PE2002000731A patent/PE20030331A1/es not_active Application Discontinuation
- 2002-12-08 UA UA2004031856A patent/UA87262C2/uk unknown
2004
- 2004-01-09 NO NO20040087A patent/NO334788B1/no not_active IP Right Cessation
- 2004-03-03 CR CR7271A patent/CR7271A/es unknown
- 2004-03-12 ZA ZA2004/02005A patent/ZA200402005B/en unknown
2017
- 2017-05-31 CY CY20171100561T patent/CY1118924T1/el unknown
2021
- 2021-08-31 CY CY20211100776T patent/CY1124763T1/el unknown

Also Published As

Publication number	Publication date
WO2003015690A2 (en)	2003-02-27
EP1441702B1 (en)	2017-05-10
GT200200164A (es)	2003-09-26
HUP0401042A2 (hu)	2004-08-30
IS3004B (is)	2018-09-15
PY0218122A (es)	2004-03-01
NZ531318A (en)	2005-08-26
AU2002326114B2 (en)	2007-03-08
BR0211855A (pt)	2004-09-21
PT3103443T (pt)	2021-08-12
AR034975A1 (es)	2004-03-24
HUP0401042A3 (en)	2009-07-28
LT1441702T (lt)	2017-06-12
CY1118924T1 (el)	2018-01-10
EP1441702A2 (en)	2004-08-04
AU2002326114A1 (en)	2003-03-03
HK1066161A1 (zh)	2005-03-18
EA200400302A1 (ru)	2004-10-28
WO2003015690B1 (en)	2004-03-11
CN100453078C (zh)	2009-01-21
ES2882584T3 (es)	2021-12-02
PL367872A1 (en)	2005-03-07
PE20030331A1 (es)	2003-06-27
EP1441702A4 (en)	2007-09-26
CR7271A (es)	2004-05-17
UY27401A1 (es)	2003-02-28
US8962024B2 (en)	2015-02-24
MXPA04001372A (es)	2005-06-06
IL144900A (en)	2013-12-31
PT1441702T (pt)	2017-06-02
ES2626591T3 (es)	2017-07-25
IL144900A0 (en)	2002-06-30
CN1541092A (zh)	2004-10-27
ZA200402005B (en)	2005-07-27
PA8552301A1 (es)	2003-06-30
CY1124763T1 (el)	2022-07-22
SI1441702T1 (sl)	2017-08-31
IS7136A (is)	2004-01-30
CA2454699A1 (en)	2003-02-27
EP3103443B1 (en)	2021-06-30
JP2005501095A (ja)	2005-01-13
US20040248966A1 (en)	2004-12-09
NO334788B2 (no)	2014-05-26
AU2002326114C1 (en)	2019-03-21
NO20040087L (no)	2004-02-19
KR20040032917A (ko)	2004-04-17
WO2003015690A3 (en)	2003-09-25
NO334788B1 (no)	2014-05-26
JO3446B1 (ar)	2020-07-05
HU230786B1 (en)	2018-05-02
RU2011131532A (ru)	2013-03-27
EP3103443A1 (en)	2016-12-14
DK1441702T3 (da)	2017-06-06
CL2002001701A1 (es)	2010-06-25
RU2560840C2 (ru)	2015-08-20
CA2454699C (en)	2012-03-27
UA87262C2 (uk)	2009-07-10

Publication	Publication Date	Title
DK1504126T3 (da)	2014-06-10	Fremgangsmåde til regulering af genekspression
DK1997512T3 (da)	2014-01-27	Fremgangsmåder til behandling af TWEAK-relaterede tilstande
DK1252824T3 (da)	2006-10-02	Fremgangsmåde til forbedring af knoglemineralisering
DK1292594T3 (da)	2004-12-06	Quinazolinderivater til behandling af tumorer
DK1259512T3 (da)	2003-12-29	Pteridinforbindelser til behandling af psoreasis
NO20035609D0 (no)	2003-12-16	Fremgangsmåte for kontinuerlig naftabehandling
NO20042026L (no)	2004-05-14	Festesystem for ben
DK1529530T5 (da)	2009-11-23	Glucokinase påvirkende forbindelser
NO20035156D0 (no)	2003-11-20	Fremgangsmåter for brönnbehandling
DE60126838D1 (de)	2007-04-05	Amidoacetonitrile zur Bekämpfung von Endoparasiten
DK1324970T3 (da)	2009-01-05	Retinoider til behandling af emfysem
DK1206436T3 (da)	2005-02-14	Retinoider til behandling af emfysem
NO20014597D0 (no)	2001-09-21	Fremgangsmåte
NO20035573D0 (no)	2003-12-12	Kinazolinderivater
DE10160799B4 (de)	2007-05-16	Zusatzheizung
DE60227963D1 (de)	2008-09-11	Behandlungssystem
DK1458386T3 (da)	2007-08-13	Aroylpyrrolheteroaryl- og methanolforbindelser til behandling af en lidelse i centralnervesystemet
FI20012170L (fi)	2003-05-10	Menetelmä lauhteiden käsittelemiseksi
NO334788B2 (no)	2014-05-26	Fremgangsmåte for behandling av søvnløshet
IS6888A (is)	2003-07-24	Aðferð við meðferð sykursýki af gerð I
DK1268482T3 (da)	2003-12-22	Pyranoindoler til behandling af glaukom
DE60232564D1 (de)	2009-07-23	Fixiergerät
DE50115676D1 (de)	2010-12-09	Heizungsanlage
DE60134712D1 (de)	2008-08-21	Regulierventil
DE50202940D1 (de)	2005-06-02	Ausrichtelement